New Study:
Lived experience of GLP-1 medications
A new study published in Diabetes, Obesity and Metabolism sheds light on the lived experiences of 1,659 individuals using GLP-1 receptor agonists for weight loss in a virtual care setting. Led by Maneeha Naveed and colleagues, the research explores the motivators, barriers, and realities of GLP-1 treatment—offering a human-centred perspective on one of the most talked-about obesity interventions of recent years.
The study reveals that over half of participants had been trying to lose weight for more than a decade before turning to GLP-1 medications like semaglutide and tirzepatide. These drugs, originally developed for type 2 diabetes, have shown remarkable promise in appetite suppression and weight reduction. But the journey is far from straightforward.
Among the most common barriers to weight loss were entrenched eating habits, stress, and menopause—factors often overlooked in traditional weight management programmes. Motivators, on the other hand, centred on reducing health risks and improving body satisfaction. Interestingly, symptom relief and increased energy emerged as unique drivers for GLP-1 users, suggesting a shift in priorities from aesthetics to wellbeing.
The study also highlights the concept of “food noise” (persistent, intrusive thoughts about food) which GLP-1s appear to quieten. Participants reported feeling more in control of their eating, with improved satiety and reduced cravings. Yet, not all experiences were positive. Side effects, cost, and unmet expectations led many to discontinue treatment, with some switching providers or abandoning medication altogether.
Video diaries added emotional depth to the data, revealing how stigma and shame influenced decisions to hide medication use. While some saw GLP-1s as a tool to support lifestyle changes, others relied solely on the medication, fearing weight regain if they stopped.
The authors call for more personalised care, including behavioural support and stress management, to improve adherence and outcomes. With obesity increasingly recognised as a chronic condition, this study underscores the need for compassionate, tailored interventions that go beyond the prescription pad.
As GLP-1s continue to reshape the landscape of obesity treatment, understanding the human stories behind the statistics may be the key to lasting change.
Translation into action
Focus on behaviour: Evidence based weight management programmes should be routinely offered to people prescribed GLP-1 medication. These ‘Tier 2’ services offer structured weekly advice alongside social support from peers.
Focus on stress: Stress is a major trigger of disordered eating. This includes overeating as well as unhealthy fasting. People prescribed GLP-1 should be signposted to sources of support for stress. These include online resources as well as community groups, especially those that focus on being outdoors or physical activity.
Focus on the long term: Weight regain is common after stopping GLP-1 medication. So ensure a long-term plan is in place from the outset. The focus on behavioural control and stress will help this. But ensure people see GLP-1 as a stepping stone to a healthier weight rather than a life-long strategy.
References
Naveed M, Perez C, Ahmad E, Russell L, Lees Z, Maybury C. GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting. Diabetes Obes Metab. 2025;27(7):3780–3788. doi:10.1111/dom.16405